Cassava's Alzheimer's drug fails in late-stage study (updated)

Filana Therapeutics

25/11/2024 12:42

(Adds details in paragraph 2,3 and 4)
       Nov 25 (Reuters) - Cassava Sciences  SAVA.O  on Monday
said its experimental Alzheimer's disease drug did not meet the
main or secondary goals in a late-stage study.
    The treatment, simufilam, failed to demonstrate a
significant reduction in cognitive or functional decline
compared to a placebo in patients with mild-to-moderate
Alzheimer's disease, the company said.
        As a result, Cassava will discontinue a second
late-stage study, as well as its open-label study of the drug.
  
        Cassava shares were halted in premarket hours ahead of
the announcement. 
  
        
  

 (Reporting by Bhanvi Satija in Bengaluru; Editing by Tasim
Zahid)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))